California's experience implementing a pilot newborn supplemental screening program using tandem mass spectrometry

被引:0
|
作者
Feuchtbaum, L
Lorey, F
Faulkner, L
Sherwin, J
Currier, R
Bhandal, A
Cunningham, G
机构
[1] Calif Dept Hlth Serv, Genet Dis Branch, Richmond, CA 94804 USA
[2] Calif Dept Hlth Serv, Genet Dis Lab, Richmond, CA 94804 USA
[3] Publ Hlth Inst, Berkeley, CA USA
关键词
newborn screening; tandem mass spectrometry; program implementation;
D O I
暂无
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
OBJECTIVE. In response to a California legislative mandate, a pilot tandem mass spectrometry (MS/MS) screening program was undertaken by the Genetic Disease Branch of the California Department of Health Services between January 2002 and June 2003. This article outlines the Genetic Disease Branch approach to implementing the MS/MS pilot program and the program evaluation strategies used. METHODS. Through the use of multiple data collection methods, we were able to describe hospital participation patterns, screening test uptake, screening test performance, follow-up services utilization, and provider and family satisfaction with the educational materials and follow-up services provided. RESULTS. During the 18-month pilot program, just more than one half of California's 755 698 newborns were offered MS/MS screening; among this group, 90% of parents chose to have their newborns screened. Fifty-one newborns were identified with MS/MS-detectable disorders, among 461 patients referred for follow-up testing (0.13% of the screened population). One disorder was diagnosed successfully for every 6939 newborns screened and for every 9 infants referred ( excluding phenylketonuria). The overall California population prevalence of MS/MS-detectable disorders was 1 case per 6500 infants ( excluding phenylketonuria). The positive predictive value for medium-chain acyl-CoA dehydrogenase deficiency was 86.7%, whereas the positive predictive value for short-chain acyl-CoA dehydrogenase deficiency was 21.6%. For a sample from Hawaii, 1 isovaleric aciduria case was detected among 6132 newborns. CONCLUSIONS. Evaluation of the California MS/MS screening pilot program demonstrated that this technology was effective in identifying additional metabolic disorders. The positive predictive value of screening was particularly good for medium-chain acyl-CoA dehydrogenase deficiency. Overall, patient referral rates were very acceptable. The utility of the program was also demonstrated by positive reviews from patients and providers.
引用
收藏
页码:S261 / S269
页数:9
相关论文
共 50 条
  • [41] Proficiency testing outcomes of 3-hydroxyisovalerylcarnitine measurements by tandem mass spectrometry in newborn screening
    Lim, Timothy H.
    De Jesus, Victor R.
    Meredith, Nancy K.
    Sternberg, Maya R.
    Chace, Donald H.
    Mei, Joanne V.
    Hannon, W. Harry
    CLINICA CHIMICA ACTA, 2011, 412 (7-8) : 631 - 635
  • [42] Making the case for objective performance metrics in newborn screening by tandem mass spectrometry
    Rinaldo, Piero
    Zafari, Saba
    Tortorelli, Silvia
    Matern, Dietrich
    MENTAL RETARDATION AND DEVELOPMENTAL DISABILITIES RESEARCH REVIEWS, 2006, 12 (04): : 255 - 261
  • [43] Disorders of Fatty Acid Oxidation in the Era of Tandem Mass Spectrometry in Newborn Screening
    Banta-Wright, Sandra A.
    Shelton, Kathleen C.
    Bennett, Michael J.
    NEWBORN AND INFANT NURSING REVIEWS, 2008, 8 (01) : 18 - 29
  • [44] Prospective diagnosis of 2-methylbutyryl-CoA dehydrogenase deficiency in the Hmong population by newborn screening using tandem mass spectrometry
    Matern, D
    He, M
    Berry, SA
    Rinaldo, P
    Whitley, CB
    Madsen, PP
    van Calcar, SC
    Lussky, RC
    Andresen, BS
    Wolff, JA
    Vockley, J
    PEDIATRICS, 2003, 112 (01) : 74 - 78
  • [45] Determination of EDTA in dried blood samples by tandem mass spectrometry avoids serious errors in newborn screening
    Fingerhut, Ralph
    Dame, Torsten
    Olgemoeller, Bernhard
    EUROPEAN JOURNAL OF PEDIATRICS, 2009, 168 (05) : 553 - 558
  • [46] Non-derivatizing Tandem Mass Spectrometry Assay for Expanded Newborn Screening and Cutoffs for Preterm Neonates
    Lee, Joon Hee
    Song, Junghan
    ANNALS OF LABORATORY MEDICINE, 2023, 43 (02) : 133 - 134
  • [47] Newborn Screening for Inborn Errors of Metabolism by Next-Generation Sequencing Combined with Tandem Mass Spectrometry
    Tang, Chengfang
    Li, Lixin
    Chen, Ting
    Li, Yulin
    Zhu, Bo
    Zhang, Yinhong
    Yin, Yifan
    Liu, Xiulian
    Huang, Cidan
    Miao, Jingkun
    Zhu, Baosheng
    Wang, Xiaohua
    Zou, Hui
    Han, Lianshu
    Feng, Jizhen
    Huang, Yonglan
    INTERNATIONAL JOURNAL OF NEONATAL SCREENING, 2024, 10 (02)
  • [48] Determination of EDTA in dried blood samples by tandem mass spectrometry avoids serious errors in newborn screening
    Ralph Fingerhut
    Torsten Dame
    Bernhard Olgemöller
    European Journal of Pediatrics, 2009, 168 : 553 - 558
  • [49] Comparison of amino acids and acylcarnitines assay methods used in newborn screening assays by tandem mass spectrometry
    De Jesus, Victor R.
    Chace, Donald H.
    Lim, Timothy H.
    Mei, Joanne V.
    Hannon, W. Harry
    CLINICA CHIMICA ACTA, 2010, 411 (9-10) : 684 - 689
  • [50] Questioning the need for informed consent: A case study of California's experience with a pilot newborn screening research project
    Feuchtbaum, Lisa
    Cunningham, George
    Sciortino, Stan
    JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS, 2007, 2 (03) : 3 - 14